ACST Acasti Pharma, Inc.

1.33
+0.06  (4.72%)
Previous Close 1.27
Open 1.27
Price To book 0.90
Market Cap 14.25M
Shares 10,712,000
Volume 211,468
Short Ratio 0.56
Av. Daily Volume 242,627

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated by the end of 2017.
CaPre (TRIFECTA trial)
Hypertriglyceridemia

Latest News

  1. Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed Offering of Units
  2. Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma
  3. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q3, 2017 By the Numbers : January 16, 2017
  4. Acasti reports 3Q loss
  5. Acasti reports 3Q loss
  6. Acasti Pharma Reports Third Quarter 2017 Financial Results
  7. Acasti Pharma Appoints Linda O'Keefe as Chief Financial Officer
  8. Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV
  9. Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre
  10. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q2, 2017 By the Numbers : October 14, 2016
  11. Acasti Pharma Reports Second Quarter 2017 Financial Results
  12. McDonald’s Corporation (MCD), AcelRx Pharmaceuticals Inc. (ACRX) & More: Here’s Why These Stocks Are Trending Today
  13. Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
  14. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q1, 2017 By the Numbers : July 22, 2016
  15. Acasti Announces the Election of its Directors, Change of Fiscal Year End and Other Related Matters Passed at its AGM
  16. Acasti Announces First Quarter Results
  17. ACASTI PHARMA INC. Financials
  18. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q4, 2016 By the Numbers : June 1, 2016
  19. Acasti Announces Grant of Stock Options
  20. Acasti Announces Fourth Quarter and Fiscal Year Results